Ann: Investor Presentation, page-7

The presentation was very helpful and sets out the case very cleanly.

I found it very good to be reminded of a few points -

No requirement for additional capital - they underlined No, not me

Enterprise value of only $10 million.

Just how good the Phase II results were and that we saw statistically significant and clinically meaningful results on both the primary and secondary endpoints. Including VISION.

We will be in Phase III trials in Europe in 6 to 9 months.

The EU is 60% of the TAM and given orphan drug designation in Europe we get 10 years of exclusivity as opposed to 7 with the same designation with the FDA.